Anti-Mullerian hormone and endometrial cancer: a multi-cohort study

Renée Turzanski-Fortner; Helena Schock; Seungyoun Jung; Naomi E. Allen; Alan A Arslan; Louise A Brinton; Brian L. Egleston; Roni T Falk; Marc J. Gunter; Kathy J Helzlsouer; Annika Idahl; Theron S Johnson; Rudolf Kaaks; Vittorio Krogh; Eva Lundin; Melissa A. Merritt; Carmen Navarro; N Charlotte Onland-Moret; Domenico Palli; Xiao Ou Shu; Patrick M. Sluss; Paul N. Staats; Antonia Trichopoulou; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F. Dorgan

doi:10.1038/bjc.2017.299

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study

Renée Turzanski-Fortner, Helena Schock, Seungyoun Jung, Naomi E. Allen, Alan A Arslan, Louise A Brinton, Brian L. Egleston, Roni T Falk, Marc J. Gunter, Kathy J Helzlsouer, Annika Idahl, Theron S Johnson, Rudolf Kaaks, Vittorio Krogh, Eva Lundin, Melissa A. Merritt, Carmen Navarro, N Charlotte Onland-Moret, Domenico Palli, Xiao Ou ShuPatrick M. Sluss, Paul N. Staats, Antonia Trichopoulou, Elisabete Weiderpass, Anne Zeleniuch-Jacquotte, Wei Zheng, Joanne F. Dorgan

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk.

METHODS: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China. We identified 329 endometrial cancer cases and 339 matched controls. Anti-Mullerian hormone concentrations in blood were quantified using an enzyme-linked immunosorbent assay. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) across tertiles and for a doubling of AMH concentrations (ORlog2). Subgroup analyses were performed by ages at blood donation and diagnosis, oral contraceptive use, and tumour characteristics.

RESULTS: Anti-Mullerian hormone was not associated with the risk of endometrial cancer overall (ORlog2: 1.07 (0.99-1.17)), or with any of the examined subgroups.

CONCLUSIONS: Although experimental models implicate AMH in endometrial cancer growth inhibition, our findings do not support a role for circulating AMH in the aetiology of endometrial cancer.

Original language	English
Pages (from-to)	1412-1418
Number of pages	7
Journal	British Journal of Cancer
Volume	117
Issue number	9
DOIs	https://doi.org/10.1038/bjc.2017.299
Publication status	Published - 2017

Keywords

Mullerian inhibiting substance
anti-Mullerian hormone
endometrial cancer
multicohort study

Access to Document

10.1038/bjc.2017.299

hormoneFinal published version, 277 KB

Cite this

Turzanski-Fortner, R., Schock, H., Jung, S., Allen, N. E., Arslan, A. A., Brinton, L. A., Egleston, B. L., Falk, R. T., Gunter, M. J., Helzlsouer, K. J., Idahl, A., Johnson, T. S., Kaaks, R., Krogh, V., Lundin, E., Merritt, M. A., Navarro, C., Onland-Moret, N. C., Palli, D., ... Dorgan, J. F. (2017). Anti-Mullerian hormone and endometrial cancer: a multi-cohort study. British Journal of Cancer, 117(9), 1412-1418. https://doi.org/10.1038/bjc.2017.299

@article{2fc4669138f240c4a6b211b4467ef748,

title = "Anti-Mullerian hormone and endometrial cancer: a multi-cohort study",

abstract = "BACKGROUND: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk.METHODS: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China. We identified 329 endometrial cancer cases and 339 matched controls. Anti-Mullerian hormone concentrations in blood were quantified using an enzyme-linked immunosorbent assay. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) across tertiles and for a doubling of AMH concentrations (ORlog2). Subgroup analyses were performed by ages at blood donation and diagnosis, oral contraceptive use, and tumour characteristics.RESULTS: Anti-Mullerian hormone was not associated with the risk of endometrial cancer overall (ORlog2: 1.07 (0.99-1.17)), or with any of the examined subgroups.CONCLUSIONS: Although experimental models implicate AMH in endometrial cancer growth inhibition, our findings do not support a role for circulating AMH in the aetiology of endometrial cancer.",

keywords = "Mullerian inhibiting substance, anti-Mullerian hormone, endometrial cancer, multicohort study",

author = "Ren{\'e}e Turzanski-Fortner and Helena Schock and Seungyoun Jung and Allen, {Naomi E.} and Arslan, {Alan A} and Brinton, {Louise A} and Egleston, {Brian L.} and Falk, {Roni T} and Gunter, {Marc J.} and Helzlsouer, {Kathy J} and Annika Idahl and Johnson, {Theron S} and Rudolf Kaaks and Vittorio Krogh and Eva Lundin and Merritt, {Melissa A.} and Carmen Navarro and Onland-Moret, {N Charlotte} and Domenico Palli and Shu, {Xiao Ou} and Sluss, {Patrick M.} and Staats, {Paul N.} and Antonia Trichopoulou and Elisabete Weiderpass and Anne Zeleniuch-Jacquotte and Wei Zheng and Dorgan, {Joanne F.}",

year = "2017",

doi = "10.1038/bjc.2017.299",

language = "English",

volume = "117",

pages = "1412--1418",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "9",

}

Turzanski-Fortner, R, Schock, H, Jung, S, Allen, NE, Arslan, AA, Brinton, LA, Egleston, BL, Falk, RT, Gunter, MJ, Helzlsouer, KJ, Idahl, A, Johnson, TS, Kaaks, R, Krogh, V, Lundin, E, Merritt, MA, Navarro, C, Onland-Moret, NC, Palli, D, Shu, XO, Sluss, PM, Staats, PN, Trichopoulou, A, Weiderpass, E, Zeleniuch-Jacquotte, A, Zheng, W & Dorgan, JF 2017, 'Anti-Mullerian hormone and endometrial cancer: a multi-cohort study', British Journal of Cancer, vol. 117, no. 9, pp. 1412-1418. https://doi.org/10.1038/bjc.2017.299

TY - JOUR

T1 - Anti-Mullerian hormone and endometrial cancer

T2 - a multi-cohort study

AU - Turzanski-Fortner, Renée

AU - Schock, Helena

AU - Jung, Seungyoun

AU - Allen, Naomi E.

AU - Arslan, Alan A

AU - Brinton, Louise A

AU - Egleston, Brian L.

AU - Falk, Roni T

AU - Gunter, Marc J.

AU - Helzlsouer, Kathy J

AU - Idahl, Annika

AU - Johnson, Theron S

AU - Kaaks, Rudolf

AU - Krogh, Vittorio

AU - Lundin, Eva

AU - Merritt, Melissa A.

AU - Navarro, Carmen

AU - Onland-Moret, N Charlotte

AU - Palli, Domenico

AU - Shu, Xiao Ou

AU - Sluss, Patrick M.

AU - Staats, Paul N.

AU - Trichopoulou, Antonia

AU - Weiderpass, Elisabete

AU - Zeleniuch-Jacquotte, Anne

AU - Zheng, Wei

AU - Dorgan, Joanne F.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk.METHODS: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China. We identified 329 endometrial cancer cases and 339 matched controls. Anti-Mullerian hormone concentrations in blood were quantified using an enzyme-linked immunosorbent assay. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) across tertiles and for a doubling of AMH concentrations (ORlog2). Subgroup analyses were performed by ages at blood donation and diagnosis, oral contraceptive use, and tumour characteristics.RESULTS: Anti-Mullerian hormone was not associated with the risk of endometrial cancer overall (ORlog2: 1.07 (0.99-1.17)), or with any of the examined subgroups.CONCLUSIONS: Although experimental models implicate AMH in endometrial cancer growth inhibition, our findings do not support a role for circulating AMH in the aetiology of endometrial cancer.

AB - BACKGROUND: The Mullerian ducts are the embryological precursors of the female reproductive tract, including the uterus; anti-Mullerian hormone (AMH) has a key role in the regulation of foetal sexual differentiation. Anti-Mullerian hormone inhibits endometrial tumour growth in experimental models by stimulating apoptosis and cell cycle arrest. To date, there are no prospective epidemiologic data on circulating AMH and endometrial cancer risk.METHODS: We investigated this association among women premenopausal at blood collection in a multicohort study including participants from eight studies located in the United States, Europe, and China. We identified 329 endometrial cancer cases and 339 matched controls. Anti-Mullerian hormone concentrations in blood were quantified using an enzyme-linked immunosorbent assay. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) across tertiles and for a doubling of AMH concentrations (ORlog2). Subgroup analyses were performed by ages at blood donation and diagnosis, oral contraceptive use, and tumour characteristics.RESULTS: Anti-Mullerian hormone was not associated with the risk of endometrial cancer overall (ORlog2: 1.07 (0.99-1.17)), or with any of the examined subgroups.CONCLUSIONS: Although experimental models implicate AMH in endometrial cancer growth inhibition, our findings do not support a role for circulating AMH in the aetiology of endometrial cancer.

KW - Mullerian inhibiting substance

KW - anti-Mullerian hormone

KW - endometrial cancer

KW - multicohort study

U2 - 10.1038/bjc.2017.299

DO - 10.1038/bjc.2017.299

M3 - Article

C2 - 28873086

SN - 0007-0920

VL - 117

SP - 1412

EP - 1418

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study

Abstract

Keywords

Access to Document

Fingerprint

Cite this